Optimal H1N1 vaccination strategies based on self-interest versus group interest

BMC Public Health

Volumn 11, Issue SUPPL. 1, 2011, Pages

  Shim, Eunha ^a,b   Meyers, Lauren Ancel ^c,d   Galvani, Alison P ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d SANTA FE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COST BENEFIT ANALYSIS; EPIDEMIC; FEMALE; HEALTH SURVEY; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; MALE; MASS IMMUNIZATION; METHODOLOGY; MIDDLE AGED; MONTE CARLO METHOD; PRESCHOOL CHILD; STATISTICAL MODEL; UNITED STATES; VACCINATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MASS VACCINATION; MIDDLE AGED; MODELS, STATISTICAL; MONTE CARLO METHOD; POPULATION SURVEILLANCE; UNITED STATES; VACCINATION;

EID: 79952547387     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-S1-S4     Document Type: Article

References (50)

1. Eurosurveillance editorial team: Pandemic alert level 6: scientific criteria for an influenza pandemic fulfilled. Euro Surveill 2009, 14(23):19237.
2. Maritz J, Maree L, Preiser W: Pandemic influenza A (H1N1) 2009: the experience of the first six months. Clin Chem Lab Med 48(1):11-21.
3. CDC: 38 Million Doses of H1N1 Vaccine Available. [http://www.flu.gov/ news/blogs/vaccine38million.html].
4. Perez-Trallero E, Pineiro L, Vicente D, Montes M, Cilla G: Residual immunity in older people against the influenza A(H1N1) - recent experience in northern Spain. Euro Surveill 2009, 14(39).
5. Bansal S, Pourbohloul B, Hupert N, Grenfell B, Meyers LA: The shifting demographic landscape of pandemic influenza. PLoS One 5(2):e9360.
6. Lee BY, Brown ST, Korch GW, Cooley PC, Zimmerman RK, Wheaton WD, Zimmer SM, Grefenstette JJ, Bailey RR, Assi TM, et al: A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine 28(31):4875-4879.
7. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K: Influenza-associated hospitalizations in the United States. JAMA 2004, 292(11):1333-1340. (Pubitemid 39223224)
8. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, Vugia D, Harriman K, Matyas B, Glaser CA, et al: Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009, 302(17):1896-1902.
9. Shim E, Chapman GB, Galvani AP: Decision making with regard to antiviral intervention during an influenza pandemic. Med Decis Making 2010, 30(4):E64-81.
10. Shim E, Kochin B, Galvani A: Insights from epidemiological game theory into gender-specific vaccination against rubella. Math Biosci Eng 2009, 6(4):839-854.
11. Influenza A (H1N1): pandemic alert phase 6 declared, of moderate severity. [http://www.euro.who.int/en/what-we-publish/information-for-themedia/ sections/press-releases/2009/06/influenza-a-h1n1-who-announcespandemic- alert-phase-6,-of-moderate-severity].
12. Shim E, Galvani AP: Impact of transmission dynamics on the costeffectiveness of rotavirus vaccination. Vaccine 2009, 27(30):4025-4030.
13. Shim E, Castillo-Chavez C: The epidemiological impact of rotavirus vaccination in the United States and Mexico. In Mathematical and Statistical Estimation Approaches in Epidemiology. Springer;Chowell G, Hyman JM, Bettencourt LMA, Castillo-Chavez C 2009:303-323.
14. 2009 H1N1 Early Outbreak and Disease Characteristics. [http://www.cdc.gov/H1N1FLU/surveillanceqa.htm].
15. Boni MF, Manh BH, Thai PQ, Farrar J, Hien TT, Hien NT, Van Kinh N, Horby P: Modelling the progression of pandemic influenza A (H1N1) in Vietnam and the opportunities for reassortment with other influenza viruses. BMC Med 2009, 7:43.
16. Presanis AM, Lipsitch M, Daniela DA, Hygiene NYCDoHaM, Team SFI, Hagy A, Reed C, Riley S, Cooper B, Biedrzycki P, et al: The severity of pandemic H1N1 influenza in the United States, April - July 2009. PLoS Currents Influenza 2009, RRN1042.
17. Kelly HA, Grant KA, Williams S, Fielding J, Smith D: Epidemiological characteristics of pandemic influenza H1N1 2009 and seasonal influenza infection. Med J Aust 2009, 191(3):146-149.
18. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, et al: Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009, 324(5934):1557-1561.
19. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, Massari M, Salmaso S, Tomba GS, Wallinga J, et al: Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008, 5(3):e74.
20. Medlock J, Galvani AP: Optimizing influenza vaccine distribution. Science 2009, 325(5948):1705-1708.
21. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK: Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med 2009.
22. Burstrom K, Johannesson M, Diderichsen F: The value of the change in health in Sweden 1980/81 to 1996/97. Health Econ 2003, 12(8):637-654.
23. Cutler DM, Richardson E: The value of health: 1970-1990. Am Econ Rev Papers Proc 1998, 88:97-100.
24. Cutler DM, Richardson E: Measuring the health of the US population. Brookings paper on economic activity. Microeconomics 1997, 217-271.
25. Meltzer MI, Cox NJ, Fukuda K: The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999, 5(5):659-671. (Pubitemid 29493768)
26. Haddix AC, Teutsch SM, Shaffer PA, Duet DO: Prevention Effectiveness New York, NY: Oxford University Press; 1996.
27. Nash JF: Equilibrium points in N-person games. PNAS 1950, 36:48-49.
28. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM Jr.: Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009, 170(6):679-686.
29. CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009 - March 13, 2010. [http://www.cdc.gov/h1n1flu/ estimates-2009-h1n1-April-March13.htm].
30. Towers S, Feng Z: Pandemic H1N1 influenza: predicting the course of a pandemic and assessing the efficacy of the planned vaccination programme in the United States. Euro Surveill 2009, 14(41):19358.
31. La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J, Gastellu-Etchegorry M: The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro Surveill 2009, 14(42).
32. Bauch CT, Galvani AP, Earn DJ: Group interest versus self-interest in smallpox vaccination policy. Proc Natl Acad Sci U S A 2003, 100(18):10564-10567. (Pubitemid 37071918)
33. Bauch C, Earn D: Vaccination and the theory of games. Proc Natl Acad Sci USA 2004, 101:13391-13394. (Pubitemid 39209676)
34. Bauch CT: Imitation dynamics predict vaccinating behaviour. Proc Biol Sci 2005, 272(1573):1669-1675.
35. Galvani AP, Reluga TC, Chapman GB: Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. PNAS 2007, 104(13):5692-5697. (Pubitemid 47175742)
36. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009, 58(RR-10):1-8.
37. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360(25):2605-2615.
38. Mathematical modelling of the pandemic H1N1 2009. Wkly Epidemiol Rec 2009, 84(34):341-348.
39. Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, Matrajt L, Potter G, Kenah E, Longini IM Jr.: The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009, 326(5953):729-733.
40. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I: Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine - preliminary report. N Engl J Med 2009.
41. Dasta JF, McLaughlin TP, Mody SH, Piech CT: Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005, 33(6):1266-1271. (Pubitemid 40827376)
42. CBA Case Study: The Economic Impact of Pandemic Influenza in the United States. [http://www.cdc.gov/owcd/EET/CBA-Case/1.html].
43. Campbell DS, Rumley MA: Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occupational Environ Med 1997, 39:408-414. (Pubitemid 27250368)
44. Kavet J: A perspective on the significance of pandemic influenza. Am J Public Health 1977, 67:1063-1070.
45. Serfling RE, Sherman IL, Houseworth WJ: Excess pneumonia-influenza mortality by age and sex in three major influenza A2 epidemics, United States, 1957-58, 1960 and 1963. Am J Epidemiol 1967, 86(2):433-441.
46. Coburn BJ, Wagner BG, Blower S: Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med 2009, 7:30.
47. Loughlin J, Wang FT, El Khoury A, Doherty M, Mast TC, Seeger JD: Adherence to the recommended pentavalent rotavirus vaccine administration schedule in the United States: 2006-2007. Pediatr Infect Dis J 2009, 28(7):667-668.
48. Presanis AM, Lipsitch M, Angelis DD, The-Swine-Flu-Infestigation-Team, N. Y.C.Department-of-Health-and-Mental-Hygiene, Hagy A, Reed C, Riley S, Cooper B, Biedrzycki P, et al: The severity of pandemic H1N1 influenza in the United States, April - July 2009. PLoS Currents Influenza 2009, RRN1042.
49. Meltzer MI, Cox NJ, Fukuda K: Modeling the economic impact of pandemic influenza in the United States: implications for setting priorities for intervention: background paper. Technical Report. 1999.
50. Neustadt RE, Fineberg HV: The Swine Flu Affair: Decision Making on a Slippery Disease. Washington, DC: National Academies Press Online; 1978.